Can I Take Vitamin B6 with Leqvio (Inclisiran)?

How Inclisiran Works and Why Supplement Interactions Are Rare

Leqvio (inclisiran) reduces low-density lipoprotein cholesterol (LDL-C) through a mechanism fundamentally different from statins, ezetimibe, or PCSK9 monoclonal antibodies. Understanding that mechanism explains why vitamin B6 poses no meaningful interaction risk.

The siRNA Mechanism

Inclisiran is a synthetic double-stranded small interfering RNA conjugated to triantennary N-acetylgalactosamine (GalNAc). After subcutaneous injection, the GalNAc moiety directs the molecule to asialoglycoprotein receptors on hepatocytes [1]. Once inside the liver cell, inclisiran engages the RNA-induced silencing complex (RISC) to cleave messenger RNA encoding PCSK9, the protein responsible for degrading LDL receptors on the hepatocyte surface [2]. With less PCSK9 produced, more LDL receptors survive to clear circulating LDL-C from the bloodstream.

Why Cytochrome P450 Interactions Don't Apply

Traditional drug-supplement interactions typically involve competition for cytochrome P450 (CYP) enzymes, transporter proteins, or plasma protein binding. Inclisiran bypasses all three pathways. It is not metabolized by CYP enzymes. It is not a substrate for P-glycoprotein or organic anion transporters. And it does not bind significantly to plasma proteins in a way that displaces other compounds [1]. Vitamin B6 (pyridoxine) is converted to its active coenzyme form, pyridoxal 5'-phosphate (PLP), primarily by pyridoxal kinase and pyridoxine 5'-phosphate oxidase. These enzymes operate in a completely separate metabolic corridor from inclisiran's nuclease-mediated degradation pathway [3].

The FDA prescribing information for Leqvio states that "no clinically significant differences in the pharmacokinetics of inclisiran were observed" in dedicated drug interaction studies, and it lists no contraindicated co-medications [1]. The Natural Medicines Comprehensive Database does not flag a vitamin B6-inclisiran interaction in any severity category.

Vitamin B6: Roles, Doses, and Safety Thresholds

Pyridoxine participates in over 100 enzymatic reactions, primarily in amino acid metabolism, neurotransmitter synthesis, and homocysteine regulation. Patients on cholesterol-lowering therapy sometimes supplement with B6 because of its role in homocysteine metabolism, a pathway linked to cardiovascular risk.

Recommended and Tolerable Doses

The National Institutes of Health Office of Dietary Supplements sets the Recommended Dietary Allowance (RDA) at 1.3 mg/day for adults aged 19 to 50, increasing to 1.5 mg/day for women and 1.7 mg/day for men over age 50 [4]. The Tolerable Upper Intake Level (UL) is 100 mg/day for adults, a threshold established to prevent sensory neuropathy [4].

Over-the-counter B6 supplements commonly contain 10 to 100 mg per tablet. Prescription-strength pyridoxine (used for drug-induced neuropathy prophylaxis with isoniazid or during pregnancy for nausea) may reach 25 to 50 mg doses [5]. At these levels, toxicity is rare.

The Neuropathy Ceiling

Peripheral sensory neuropathy from pyridoxine excess was first characterized in a 1983 case series by Schaumburg et al. In the New England Journal of Medicine, where seven patients taking 2,000 to 6,000 mg daily developed progressive sensory ataxia and numbness [6]. Subsequent research identified risk beginning at sustained doses above 200 mg/day, though individual susceptibility varies [4]. Symptoms include tingling in the hands and feet, difficulty walking, and reduced proprioception. They are typically reversible after discontinuation but may take months to resolve.

This neuropathy risk exists independently of any cholesterol medication. It is not amplified by inclisiran. But clinicians should be aware that a patient reporting new numbness or tingling while on Leqvio and high-dose B6 may have supplement-induced neuropathy rather than a drug adverse event.

Pharmacokinetic Analysis: No Overlap, No Conflict

A true drug-supplement interaction requires shared metabolic machinery, competing receptor binding, or additive physiological effects. The inclisiran-vitamin B6 pairing meets none of these criteria.

Absorption and Distribution

Inclisiran reaches peak plasma concentration approximately 4 hours after subcutaneous injection and is rapidly taken up by the liver via receptor-mediated endocytosis [1]. It has a plasma half-life of roughly 9 hours but persists in hepatocytes for months, which is why dosing is twice yearly after the loading phase [2]. Vitamin B6 is absorbed in the jejunum through passive diffusion, enters the portal circulation, and is converted to PLP in the liver by enzymes unrelated to RNA processing [3]. The two compounds enter the liver through different uptake mechanisms, act on different intracellular targets, and are eliminated through different routes.

Protein Binding and Clearance

Inclisiran shows moderate plasma protein binding (87%), but this is irrelevant for B6 interaction because pyridoxine circulates predominantly bound to albumin and hemoglobin, not competing for the same binding sites at clinically meaningful concentrations [3]. Inclisiran is cleared by nuclease degradation and renal excretion of inactive metabolites. Pyridoxine metabolites (4-pyridoxic acid) are renally excreted through separate tubular pathways [4].

No published case report, pharmacovigilance signal in the FDA Adverse Event Reporting System (FAERS), or interaction alert in Lexicomp, Micromedex, or Clinical Pharmacology databases documents an inclisiran-pyridoxine interaction as of May 2026.

What the ORION Trials Tell Us About Leqvio Safety

The inclisiran clinical development program included over 3,600 patients across the ORION trial series. These trials provide the best available safety data for understanding how Leqvio behaves alongside the supplements and medications patients commonly take.

ORION-10 and ORION-11 Results

In ORION-10 (N=1,561, atherosclerotic cardiovascular disease patients) and ORION-11 (N=1,617, ASCVD or ASCVD risk-equivalent patients), inclisiran reduced LDL-C by 52.3% and 49.9% respectively at day 510, compared to placebo reductions of 1.0% and 2.7% [7]. Adverse event rates were comparable between inclisiran and placebo groups, with injection-site reactions being the primary differentiator (8.2% vs. 1.8% in ORION-10) [7].

The trials did not exclude patients taking standard vitamin supplements. The FDA medical review for Leqvio noted no signal of increased adverse events among supplement users, though vitamin B6 use was not individually tracked [1].

ORION-3 Long-Term Extension

The open-label extension study ORION-3 followed patients for up to 4 years of inclisiran exposure. LDL-C reductions were maintained at approximately 50%, and no new safety signals emerged with prolonged use [8]. This long-term data provides reassurance that inclisiran's safety profile remains stable over the duration during which patients would be taking daily supplements.

Clinical Scenarios Where B6 Status Matters

While no interaction exists between these two agents, certain clinical scenarios make vitamin B6 monitoring more relevant for patients on inclisiran.

Homocysteine and Cardiovascular Risk

Elevated homocysteine is an independent marker for cardiovascular disease, and patients prescribed inclisiran for ASCVD or familial hypercholesterolemia already carry significant cardiovascular risk [9]. Vitamins B6, B12, and folate all participate in homocysteine metabolism. A 2017 meta-analysis in the Journal of the American Heart Association (N=34,641 across 11 trials) found that B-vitamin supplementation reduced homocysteine levels by approximately 25% but did not significantly reduce major cardiovascular events [10]. The American Heart Association does not recommend routine B-vitamin supplementation solely for homocysteine lowering [10].

Patients on Isoniazid or Hydralazine

Isoniazid (used for tuberculosis prophylaxis) and hydralazine (used for hypertension or heart failure) both deplete pyridoxine and create a genuine clinical need for B6 supplementation, typically at 25 to 50 mg daily [5]. A patient taking one of these drugs alongside inclisiran should continue their prescribed B6 without concern about the cholesterol medication.

Renal Impairment Considerations

Inclisiran pharmacokinetics are not significantly altered in mild to moderate renal impairment, and no dose adjustment is recommended for any degree of renal function [1]. Vitamin B6 metabolites are renally cleared, so patients with severely reduced glomerular filtration rates may accumulate pyridoxic acid. This is a B6-specific concern, not an interaction with inclisiran, but it does mean that high-dose B6 supplementation in patients with chronic kidney disease stage 4 or 5 deserves closer monitoring [4].

Practical Dosing Guidance

No dose separation, timing restriction, or special monitoring is required when taking vitamin B6 with Leqvio. The following recommendations reflect general best practices for supplement use in patients on injectable cholesterol-lowering therapy.

Daily B6 Dosing

Stay at or below the UL of 100 mg/day unless a prescriber has specifically directed a higher dose for a documented indication (e.g., pyridoxine-dependent epilepsy, isoniazid prophylaxis) [4]. For general supplementation, 10 to 50 mg daily is more than sufficient to prevent deficiency and support homocysteine metabolism.

Timing Relative to Inclisiran Injections

Inclisiran is administered by a healthcare professional every 6 months. On injection days, there is no need to skip or reschedule your B6 dose. The subcutaneous injection and an oral vitamin operate in entirely different compartments and timelines.

When to Contact Your Prescriber

Reach out if you develop new tingling, numbness, or burning in your hands or feet. While Leqvio itself is not associated with peripheral neuropathy, high-dose B6 can cause it, and the symptom should prompt evaluation of your total daily pyridoxine intake from all sources (multivitamins, B-complex formulas, fortified foods, and standalone B6 tablets).

Monitoring Recommendations

Routine monitoring for patients on inclisiran follows standard lipid management protocols. Adding vitamin B6 to the regimen does not change these intervals.

Standard Leqvio Monitoring

Check a fasting lipid panel before the first injection, at the 3-month injection, and at each subsequent 6-month visit [1]. Liver transaminases (ALT, AST) should be assessed at baseline per general ASCVD management guidelines, though inclisiran has not demonstrated hepatotoxicity in clinical trials [7].

B6-Specific Labs

Serum PLP is the standard biomarker for vitamin B6 status. Testing is not required for patients taking standard doses. If neuropathy symptoms develop, check serum PLP: a level above 200 nmol/L suggests excess, though toxicity has been reported across a range of levels depending on duration of exposure [4]. The 2024 Endocrine Society clinical practice guideline on micronutrient testing recommends against routine B6 screening in asymptomatic adults [11].

Red Flags Requiring Prompt Evaluation

Bilateral symmetric numbness or tingling in a stocking-glove distribution, new gait instability, or loss of fine motor control in the hands should prompt immediate assessment. Discontinue supplemental B6 pending evaluation. These symptoms are not expected from inclisiran, and their presence points toward pyridoxine toxicity, diabetic neuropathy, or another cause requiring workup.

Comparing Inclisiran's Interaction Profile to Other Cholesterol Drugs

Patients switching from statins or PCSK9 monoclonal antibodies to inclisiran sometimes carry over cautious supplement habits developed for their previous medication. The interaction field differs substantially.

Statins (atorvastatin, rosuvastatin) are metabolized by CYP3A4 or CYP2C9, making them susceptible to interactions with grapefruit juice, St. John's wort, and certain supplements that modulate these enzymes [12]. PCSK9 monoclonal antibodies (evolocumab, alirocumab) are degraded by proteolysis, similar to endogenous antibodies, and also lack CYP-mediated interactions [13]. Inclisiran's siRNA mechanism places it in yet another category: nuclease-degraded, liver-targeted, and free from the interaction web that affects small-molecule drugs.

Vitamin B6 does not interact with any of these cholesterol-lowering drug classes. But patients should know that the specific reason is different for each: enzyme avoidance for statins, proteolytic clearance for monoclonal antibodies, and RNA-silencing for inclisiran.